Article type
Year
Abstract
Background: in chronic kidney disease (CKD), nutritional disorders are frequent and have a direct influence on patients' quality of life. Sarcopenia is characterized by loss of muscle mass, and is associated with loss of muscle strength, or performance, or both. Among geriatric syndromes, sarcopenia is related to increased costs, incidence of falls, increased rates of hospital readmission, and mortality.
Objectives: to search the literature for observational scientific papers that assess the prevalence of sarcopenia in patients with CKD in both dialysis (hemodialysis and peritoneal dialysis) modalities.
Methods: the search for studies was carried out in the following databases: PubMed, VHL, SciELO and LILACS. Eligible studies for this review were observational-type, cohort, non-randomized clinical trials, and reviews of sarcopenia in CKD, with no restrictions regarding time or language of publication. We excluded studies that addressed sarcopenia in patients with chronic renal disease who were on conservative treatment, not performing dialysis treatment, randomized clinical trials and intervention. The Portuguese DeCS terms used in searching were: Sarcopenia, Renal Dialysis, Peritoneal Dialysis, Chronic Renal Insufficiency. The English DeCS terms used were: Sarcopenia, Renal Dialysis, Peritoneal Dialysis, Renal Insufficiency Chronic.
Results: we found a total of 157 studies: PubMed yielded 86 studies; BVS 42 studies; SciELO 15 studies; and LILACS 14 studies. We excluded 105 duplicate records. After reviewing the eligible studies, we included 13 in this review: seven studies on CKD and hemodialysis, five studies addressing CKD and peritoneal, and only one study with the two dialysis modalities.
Conclusions: sarcopenia is a syndrome with a prevalence of 20% to 42% in patients with chronic renal disease undergoing dialysis, and has an impact on the mortality of this population. A systematic review of this subject would be relevant for the implementation of evidence-based prevention and treatment strategies for this syndrome.
Patient or healthcare consumer involvement: patients with renal chronic disease should be evaluated for nutritional aspects as it is related to quality of life.
Objectives: to search the literature for observational scientific papers that assess the prevalence of sarcopenia in patients with CKD in both dialysis (hemodialysis and peritoneal dialysis) modalities.
Methods: the search for studies was carried out in the following databases: PubMed, VHL, SciELO and LILACS. Eligible studies for this review were observational-type, cohort, non-randomized clinical trials, and reviews of sarcopenia in CKD, with no restrictions regarding time or language of publication. We excluded studies that addressed sarcopenia in patients with chronic renal disease who were on conservative treatment, not performing dialysis treatment, randomized clinical trials and intervention. The Portuguese DeCS terms used in searching were: Sarcopenia, Renal Dialysis, Peritoneal Dialysis, Chronic Renal Insufficiency. The English DeCS terms used were: Sarcopenia, Renal Dialysis, Peritoneal Dialysis, Renal Insufficiency Chronic.
Results: we found a total of 157 studies: PubMed yielded 86 studies; BVS 42 studies; SciELO 15 studies; and LILACS 14 studies. We excluded 105 duplicate records. After reviewing the eligible studies, we included 13 in this review: seven studies on CKD and hemodialysis, five studies addressing CKD and peritoneal, and only one study with the two dialysis modalities.
Conclusions: sarcopenia is a syndrome with a prevalence of 20% to 42% in patients with chronic renal disease undergoing dialysis, and has an impact on the mortality of this population. A systematic review of this subject would be relevant for the implementation of evidence-based prevention and treatment strategies for this syndrome.
Patient or healthcare consumer involvement: patients with renal chronic disease should be evaluated for nutritional aspects as it is related to quality of life.
PDF